Results 131 to 140 of about 26,294 (312)

Lingual Dyskinesia as the Presenting Feature of Acquired Demyelinating Syndrome: A Case Report and Review of Differential Diagnoses

Journal of Paediatrics and Child Health, EarlyView.
Briana Davis, Ahmed Kaki, Eppie M. Yiu, Emma Macdonald‐Laurs   +3 more
wiley   +1 more source

Magnitude, Preventability, and Determinants of Adverse Drug Reactions Among Hospitalized Obstetric Patients in Ethiopia: A Prospective Observational Study

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Adverse drug reactions (ADRs) are an important and potentially preventable cause of morbidity among hospitalized obstetric patients, with implications for both maternal and fetal safety, yet evidence from low‐resource settings remains limited.
Getachew Yitayew Tarekegn, Endalemaw Tsegaw, Fisseha Nigussie Dagnew, Sisay Sitotaw Anberbr, Tilaye Arega Moges, Samuel Berihun Dagnew, Samuel Agegnew Wondm, Tigabu Eskeziya Zerihun, Abel Temeche Kassaw, Desalegn Addis Mussie   +9 more
wiley   +1 more source

The antiemetic efficacy of tropisetron plus dexamethasone as compared with conventional metoclopramide‐dexamethasone combination in Orientals receiving cisplatin chemotherapy: a randomized crossover trial [PDF]

, 1996
Daniel T. T. Chua, J. S. T. SHAM, G.K.H. Au, Damon Choy, Dora L.�W. Kwong, CC Yau, Ashely C.K. Cheng   +6 more
openalex   +1 more source

Trastuzumab Deruxtecan for HER2‐Low Metastatic Breast Cancer: Practical Considerations for Medical Oncologists and Pathologists in Australia

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 381-391, June 2026.
ABSTRACT Trastuzumab deruxtecan (T‐DXd) is a third‐generation, HER2‐targeting antibody‐drug conjugate that has been shown to significantly prolong overall survival, compared with standard chemotherapy, when used to treat patients who have “HER2‐low” (HER2 immunohistochemistry [IHC] score 1+; or HER2 IHC 2+ plus in situ hybridization‐negative ...
Andrew Redfern, Elgene Lim, Sunil Lakhani, Nirmala Pathmanathan, Sudarsha Selva‐Nayagam, Nicole McCarthy, Belinda Yeo, Benjamin Dessauvagie, Gelareh Farshid   +8 more
wiley   +1 more source

Computer Library Literature Review on Effectiveness of Antimotion Sickness Drugs [PDF]

Physiological responses to antimotion sickness drugs - antihistamines, belladonnas, and ...
Graybiel, A., Kennedy, R. S., Trumbull, R., Wherry, R. J., Jr., Wood, C. D.   +4 more
core   +1 more source

Cost-effectiveness analysis of tropisetron vs. chlorpromazine-dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children [PDF]

, 1999
To perform a cost-effectiveness analysis (CEA) between a standard antiemetic regimen-chlorpromazine + dexamethasone (CPM-DEX)- and a 5-HT3 receptor antagonist-tropisetron (TROP)--in the control of acute emesis induced by highly ...
Giraldez, J. (J.), Jimenez, M. (Miguel), Sierrasesumaga, L. (Luis), Tejedor, I. (I.)   +3 more
core  

How Does Symptom Management Affect Quality of Life in Palliative Care Patients? A Descriptive and Correlation Study

Scandinavian Journal of Caring Sciences, Volume 40, Issue 2, June 2026.
ABSTRACT Aims This study aimed to determine the relationship between symptom management and quality of life in palliative care patients. Methods Data was collected using the Patient Information Form, the Edmonton Symptom Assessment Scale (ESAS), and the EQ‐5D Quality of Life Scale.
Gülşah Çamcı, Sıdıka Oğuz, Gülsüm Betül Uçar, Pınar Yarman   +3 more
wiley   +1 more source

Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis

Frontiers in Oncology
BackgroundThe effectiveness of a dexamethasone-sparing strategy in the treatment of breast cancer with anthracycline-cyclophosphamide therapy when combined with first-generation 5-HT3 receptor antagonists (RAs) and neurokinin-1 RAs is unclear.
Daichi Watanabe, Daichi Watanabe, Hirotoshi Iihara, Hirotoshi Iihara, Hirotoshi Iihara, Ryo Kobayashi, Ryo Kobayashi, Hironori Fujii, Ryutaro Mori, Keisuke Kumada, Keisuke Kumada, Masahito Shimizu, Masahito Shimizu, Manabu Futamura, Akio Suzuki, Akio Suzuki   +15 more
doaj   +1 more source

Acute Systemic Complications Following High‐Dose Semaglutide Reinitiation in an Elderly Patient

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Severe gastrointestinal intolerance with systemic complications can occur within hours of reinitiating high‐dose semaglutide after a prolonged treatment interruption, even in patients who previously tolerated the medication. Elderly patients with comorbidities may be particularly vulnerable.
Jay Mehta, Brent Tai, Johnathan Frunzi
wiley   +1 more source

Evaluating the antiemetic administration consistency to prevent chemotherapy-induced nausea and vomiting with the standard guidelines: a prospective observational study

Therapeutics and Clinical Risk Management, 2017
Afsaneh Vazin, Davood Eslami, Ebrahim Sahebi Department of Clinical Pharmacy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran Abstract: Nausea and vomiting (NV) are the most prevalent adverse effects of chemotherapy (CT).
Vazin A, Eslami D, Sahebi E
doaj